Clinical Trial Update: A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating RC48-ADC plus toripalimab for first-line urothelial carcinoma (HER2-expressing). Status: recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)
• Toripalimab (Toripalimab)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Urothelial Carcinoma, HER2-expressing | Phase 3 | Status: RECRUITING